Investigational treatments for postoperative surgical site infections

Bibliography

• COHEN M: Epidemiology of drug resistance: implications of a post-antibiotic era. Science (1992) 257(5073):1050-1055.
   PubMed Web of Science ®Google Scholar
• DIEKEMA DJ, BOOTSMILLER BJ, VAUGHN TE et al.: Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin. Infect. Dis. (2004) 38(1):78-85.
   PubMed Web of Science ®Google Scholar
• CANTON R, COQUE TM, BAQUERO F: Multi-resistant Gram-negative bacilli: from epidemics to endemics. Curr. Opin. Infect. Dis. (2003) 16(4):315-325.
   PubMed Web of Science ®Google Scholar
• LEE SY, KUTI JL, NICOLAU DP: Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. (Larchmt.) (2005) 6(3):283-295.
   PubMedGoogle Scholar
• SPELLBERG B, POWERS JH, BRASS EP, MILLER LG, EDWARDS JE Jr: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38(9):1279-1286.
   PubMed Web of Science ®Google Scholar
• SHLAES DM: The abandonment of antibacterials: why and wherefore? Curr. Opin. Pharmacol. (2003) 3(5):470-473.
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. (2004) 32(8):470-485.
   PubMed Web of Science ®Google Scholar
• WALLACE WC, CINAT ME, NASTANSKI F, GORNICK WB, WILSON SE: New epidemiology for postoperative nosocomial infections. Am. Surg. (2000) 66(9):874-878.
   PubMed Web of Science ®Google Scholar
• GIACOMETTI A, CIRIONI O, SCHIMIZZI AM et al.: Epidemiology and microbiology of surgical wound infections. J. Clin. Microbiol. (2000) 38(2):918-922.
   PubMed Web of Science ®Google Scholar
• VAN LOOVEREN M, GOOSSENS H: Antimicrobial resistance of Acinetobacter spp. in Europe. Clin. Microbiol. Infect. (2004) 10(8):684-704.
   PubMed Web of Science ®Google Scholar
• TALBOT GH, BRADLEY J, EDWARDS JE Jr et al.: Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. (2006) 42(5):657-668.
   PubMed Web of Science ®Google Scholar
• PATERSON DL: Clinical experience with recently approved antibiotics. Curr. Opin. Pharmacol. (2006) 6(5):486-490.
   PubMed Web of Science ®Google Scholar
• GONZALES RD, SCHRECKENBERGER PC, GRAHAM MB et al.: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet (2001) 357(9263):1179.
   PubMed Web of Science ®Google Scholar
• ROBERTS SM, FREEMAN AF, HARRINGTON SM et al.: Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr. Infect. Dis. J. (2006) 25(6):562-564.
   PubMed Web of Science ®Google Scholar
• ATTASSI K, HERSHBERGER E, ALAM R, ZERVOS MJ: Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. (2002) 34(5):695-698.
   PubMed Web of Science ®Google Scholar
• GERSON SL, KAPLAN SL, BRUSS JB et al.: Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. (2002) 46(8):2723-2726.
   PubMed Web of Science ®Google Scholar
• BRESSLER AM, ZIMMER SM, GILMORE JL, SOMANI J: Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. (2004) 4(8):528-531.
   PubMed Web of Science ®Google Scholar
• DE VRIESE AS, COSTER RV, SMET J et al.: Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. (2006) 42(8):1111-1117.
   PubMed Web of Science ®Google Scholar
• LINDEN PK: Treatment options for vancomycin-resistant enterococcal infections. Drugs (2002) 62(3):425-441.
   PubMed Web of Science ®Google Scholar
• ALLINGTON DR, RIVEY MP: Quinupristin/dalfopristin: a therapeutic review. Clin. Ther. (2001) 23(1):24-44.
   PubMed Web of Science ®Google Scholar
• RUBINSTEIN E, PROKOCIMER P, TALBOT GH: Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J. Antimicrob. Chemother. (1999) 44(Suppl. A):37-46.
   PubMed Web of Science ®Google Scholar
• RAAD I, HACHEM R, HANNA H: Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction. J. Antimicrob. Chemother. (2004) 53(6):1105-1108.
   PubMed Web of Science ®Google Scholar
• CARVER PL, WHANG E, VANDENBUSSCHE HL, KAUFFMAN CA, MALANI PN: Risk factors for arthralgias or myalgias associated with quinupristin–dalfopristin therapy. Pharmacotherapy (2003) 23(2):159-164.
   PubMed Web of Science ®Google Scholar
• KASBEKAR N: Tigecycline: a new glycylcycline antimicrobial agent. Am. J. Health Syst. Pharm. (2006) 63(13):1235-1243.
   PubMed Web of Science ®Google Scholar
• NOSKIN GA: Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. (2005) 41(Suppl. 5):S303-S314.
   PubMed Web of Science ®Google Scholar
• DEAN CR, VISALLI MA, PROJAN SJ, SUM PE, BRADFORD PA: Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. (2003) 47(3):972-978.
   PubMed Web of Science ®Google Scholar
• RUZIN A, VISALLI MA, KEENEY D, BRADFORD PA: Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2005) 49(3):1017-1022.
   PubMed Web of Science ®Google Scholar
• KITZIS MD, LY A, GOLDSTEIN FW: In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2004) 48(1):366-367.
   PubMed Web of Science ®Google Scholar
• CERCENADO E, CERCENADO S, GOMEZ JA, BOUZA E: In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J. Antimicrob. Chemother. (2003) 52(1):138-139.
   PubMed Web of Science ®Google Scholar
• LABTHAVIKUL P, PETERSEN PJ, BRADFORD PA: In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob. Agents Chemother. (2003) 47(12):3967-3969.
   PubMed Web of Science ®Google Scholar
• MILATOVIC D, SCHMITZ FJ, VERHOEF J, FLUIT AC: Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. (2003) 47(1):400-404.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM CV, WARREN Y, TYRRELL K: Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. (2000) 44(10):2747-2751.
   PubMed Web of Science ®Google Scholar
• SOULI M, KONTOPIDOU FV, KORATZANIS E et al.: In vitro activity of tigecycline against multiple-drug resistant Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. (2006) 50(9):3166-3169.
   PubMed Web of Science ®Google Scholar
• BIEDENBACH DJ, BEACH ML, JONES RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. (2001) 40(4):173-177.
   PubMed Web of Science ®Google Scholar
• JACOBUS NV, McDERMOTT LA, RUTHAZER R, SNYDMAN DR: In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. (2004) 48(3):1034-1036.
   PubMed Web of Science ®Google Scholar
• WALLACE RJ Jr, BROWN BA, GRIFFITH DE: Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Ann. Rev. Microbiol. (1998) 52:453-490.
   PubMed Web of Science ®Google Scholar
• ELLIS-GROSSE EJ, BABINCHAK T, DARTOIS N, ROSE G, LOH E: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase III comparison studies with vancomycin–aztreonam. Clin. Infect. Dis. (2005) 41(Suppl. 3):S341-S353.
   PubMed Web of Science ®Google Scholar
• BABINCHAK T, ELLIS-GROSSE E, DARTOIS N, ROSE GM, LOH E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. (2005) 41(Suppl. 5):S354-S367.
   PubMed Web of Science ®Google Scholar
• LIVERMORE DM: Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. (2005) 56(4):611-614.
   PubMed Web of Science ®Google Scholar
• AKINS RL, RYBAK MJ: Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (2001) 45(2):454-459.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ: The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin. Microbiol. Infect. (2006) 12(Suppl. 1):24-32.
   PubMed Web of Science ®Google Scholar
• EISENSTEIN BI: Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin. Investig. Drugs (2004) 13(9):1159-1169.
   PubMed Web of Science ®Google Scholar
• ARBEIT RD, MAKI D, TALLY FP, CAMPANARO E, EISENSTEIN BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. (2004) 38(12):1673-1681.
   PubMed Web of Science ®Google Scholar
• LAPLANTE KL, RYBAK MJ: Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (2004) 48(12):4665-4672.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, BAILEY EM, LAMP KC, KAATZ GW: Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for Gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. (1992) 36(5):1109-1114.
   PubMed Web of Science ®Google Scholar
• TEDESCO KL, RYBAK MJ: Daptomycin. Pharmacotherapy (2004) 24(1):41-57.
   PubMed Web of Science ®Google Scholar
• ECHEVARRIA K, DATTA P, CADENA J, LEWIS JS II: Severe myopathy and possible hepatotoxicity related to daptomycin. J. Antimicrob. Chemother. (2005) 55(4):599-600.
   PubMed Web of Science ®Google Scholar
• GIAMARELLOU E: Treatment options for multidrug-resistant bacteria. Expert Rev. Anti Infect. Ther. (2006) 4(4):601-618.
   PubMedGoogle Scholar
• MOHAN SS, McDERMOTT BP, CUNHA BA: Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung (2005) 34(1):69-71.
   PubMed Web of Science ®Google Scholar
• FOWLER VG Jr, BOUCHER HW, COREY GR et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. (2006) 355(7):653-665.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, MORTIN LI, VANPRAAGH AD, LI T, ALDER J: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. (2005) 191(12):2149-2152.
   PubMed Web of Science ®Google Scholar
• CUI L, TOMINAGA E, NEOH HM, HIRAMATSU K: Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2006) 50(3):1079-1082.
   PubMed Web of Science ®Google Scholar
• EUROPEAN COMMITTEE ONANTIMICROBIAL SUSCEPTIBILITY TESTING (EUCAST) STEERING COMMITTEE:EUCAST technical note on daptomycin. Clin. Microbiol. Infect. (2006) 12(6):599-601.
   PubMed Web of Science ®Google Scholar
• JONES RN, FRITSCHE TR, SADER HS, GOLDSTEIN BP: Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. (2005) 17(6):593-600.
   Web of Science ®Google Scholar
• GOLDSTEIN EJ, CITRON DM, WARREN YA et al.: In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother. (2006) 50(8):2875-2879.
   PubMed Web of Science ®Google Scholar
• LIN SW, CARVER PL, DEPESTEL DD: Dalbavancin: a new option for the treatment of Gram-positive infections. Ann. Pharmacother. (2006) 40(3):449-460.
   PubMed Web of Science ®Google Scholar
• PACE JL, YANG G: Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. (2006) 71(7):968-980.
   PubMed Web of Science ®Google Scholar
• NORD CE, RASMANIS G, WAHLUND E: Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother. (2006) 58(3):627-631.
   PubMed Web of Science ®Google Scholar
• RAAD I, DAROUICHE R, VAZQUEZ J et al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis. (2005) 40(3):374-380.
   PubMed Web of Science ®Google Scholar
• SELTZER E, DORR MB, GOLDSTEIN BP et al.: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. (2003) 37(10):1298-1303.
   PubMed Web of Science ®Google Scholar
• JAUREGUI LE, BABAZADEH S, SELTZER E et al.: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. (2005) 41(10):1407-1415.
   PubMed Web of Science ®Google Scholar
• DAROUICHE RO, MANSOURI MD: Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect. (2005) 50(3):206-209.
   PubMed Web of Science ®Google Scholar
• MACONE A DJ, DUMONT T, LEVY SB, TANAKA SK: In vitro activity of PTK-0796 (BAY-736944) against Gram-positive and Gram-negative organisms. 43rd ICAAC, Chicago, USA (14 – 17 September 2003).
   Google Scholar
• McKENNEY DQJ, JACKSON CL, GUILMET JL, LANDRY JA, TANAKA SK, CANNON EP: Evaluation of PTK-0796 (BAY-736944) in experimental models if infections caused by Gram-positive and Gram-negative pathogens. 43rd ICAAC, Chicago, USA (14 – 17 September 2003).
   Google Scholar
• Ceftobiprole Medocaril: BAL-5788, JNJ-30982081, JNJ-30982081, RO-65-5788, RO-655788. Drugs R D (2006) 7(5):305-311.
   PubMedGoogle Scholar
• DAVIES TA, SHANG W, BUSH K: Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother. (2006) 50(7):2530-2532.
   PubMed Web of Science ®Google Scholar
• DESHPANDE L, RHOMBERG PR, FRITSCHE TR, SADER HS, JONES RN: Bactericidal activity of BAL-9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. (2004) 50(1):73-75.
   PubMed Web of Science ®Google Scholar
• DENIS O, DEPLANO A, NONHOFF C et al.: In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob. Agents Chemother. (2006) 50(8):2680-2685.
   PubMed Web of Science ®Google Scholar
• VON EIFF C, FRIEDRICH AW, BECKER K, PETERS G: Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob. Agents Chemother. (2005) 49(10):4372-4374.
   PubMed Web of Science ®Google Scholar
• BOGDANOVICH T, CLARK C, EDNIE L et al.: Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. (2006) 50(6):2050-2057.
   PubMed Web of Science ®Google Scholar
• WOOTTON M, BOWKER KE, HOLT HA, MacGOWAN AP: BAL-9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J. Antimicrob. Chemother. (2002) 49(3):535-539.
   PubMed Web of Science ®Google Scholar
• DESHPANDE LM, JONES RN: Bactericidal activity and synergy studies of BAL-9141, a novel pyrrolidinone- 3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. (2003) 9(11):1120-1124.
   PubMed Web of Science ®Google Scholar
• CHAMBERS HF: Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49(3):884-888.
   PubMed Web of Science ®Google Scholar
• ROUSE MS, HEIN MM, ANGUITA-ALONSO P, STECKELBERG JM, PATEL R: Ceftobiprole medocaril (BAL-5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. (2006) 55(4):333-336.
   PubMed Web of Science ®Google Scholar
• VAUDAUX P, GJINOVCI A, BENTO M et al.: Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49(9):3789-3793.
   PubMed Web of Science ®Google Scholar
• SCHMITT-HOFFMANN A, NYMAN L, ROOS B et al.: Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL-5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48(7):2576-2580.
   PubMed Web of Science ®Google Scholar
• OKAMOTO K, GOTOH N, NISHINO T: Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob. Agents Chemother. (2001) 45(7):1964-1971.
   PubMed Web of Science ®Google Scholar
• DALHOFF A, JANJIC N, ECHOLS R: Redefining penems. Biochem. Pharmacol. (2006) 71(7):1085-1095.
   PubMed Web of Science ®Google Scholar
• CRITCHLEY IA, KARLOWSKY JA, DRAGHI DC et al.: Activities of faropenem, an oral β-lactam, against recent US isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. (2002) 46(2):550-555.
   PubMed Web of Science ®Google Scholar
• WEXLER HM, MOLITORIS D, ST JOHN S et al.: In vitro activities of faropenem against 579 strains of anaerobic bacteria. Antimicrob. Agents Chemother. (2002) 46(11):3669-3675.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM CV et al.: Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J. Antimicrob. Chemother. (2002) 50(3):411-420.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA T, MATSUZAKI K, KOYAMA H et al.: [In vitro activity of faropenem against β-lactamase producing clinical isolates]. Jpn. J. Antibiot. (2000) 53(3):179-183.
   PubMedGoogle Scholar
• PIDDOCK LJ, JOHNSON MM, WEBBER MA: Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria. J. Antimicrob. Chemother. (2003) 52(3):500-502.
   PubMed Web of Science ®Google Scholar
• JONES RN, SADER HS, FRITSCHE TR: Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. (2005) 52(1):71-74.
   PubMed Web of Science ®Google Scholar
• MORI M, HIKIDA M, NISHIHARA T, NASU T, MITSUHASHI S: Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother. (1996) 37(5):1034-1036.
   PubMed Web of Science ®Google Scholar
• TSUJI M, ISHII Y, OHNO A, MIYAZAKI S, YAMAGUCHI K: In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. (1998) 42(1):94-99.
   PubMed Web of Science ®Google Scholar
• WATANABE A, TAKAHASHI H, KIKUCHI T et al.: Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy (2000) 46(3):184-187.
   PubMed Web of Science ®Google Scholar
• MUSHTAQ S, GE Y, LIVERMORE DM: Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. (2004) 48(8):3086-3092.
   PubMed Web of Science ®Google Scholar
• JONES RN, HUYNH HK, BIEDENBACH DJ, FRITSCHE TR, SADER HS: Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. (2004) 54(1):144-154.
   PubMed Web of Science ®Google Scholar
• WEXLER HM, ENGEL AE, GLASS D, LI C: In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob. Agents Chemother. (2005) 49(10):4413-4417.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI Y: Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J. Infect. Chemother. (2005) 11(5):259-261.
   PubMedGoogle Scholar
• ALEKSHUN MN: New advances in antibiotic development and discovery. Expert Opin. Investig. Drugs (2005) 14(2):117-134.
   PubMed Web of Science ®Google Scholar
• HORIUCHI M, KIMURA M, TOKUMURA M et al.: Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology (2006) 222(1-2):114-124.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA Y, MIZOBUCHI M, NAKAMURA M et al.: Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab. Dispos. (2004) 32(12):1383-1391.
   PubMed Web of Science ®Google Scholar
• FETTERLY GJ, ONG CM, BHAVNANI SM et al.: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob. Agents Chemother. (2005) 49(1):148-152.
   PubMed Web of Science ®Google Scholar
• JONES RN, HUYNH HK, BIEDENBACH DJ: Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. (2004) 48(8):3136-3140.
   PubMed Web of Science ®Google Scholar
• KAWAMOTO I, SHIMOJI Y, KANNO O et al.: Synthesis and structure–activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J. Antibiot. (Tokyo) (2003) 56(6):565-579.
   PubMed Web of Science ®Google Scholar
• GUIGNARD B, ENTENZA JM, MOREILLON P: β-lactams against methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol. (2005) 5(5):479-489.
   PubMed Web of Science ®Google Scholar
• KOGA T, ABE T, INOUE H et al.: In vitro and in vivo antibacterial activities of CS-023 (RO-4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother. (2005) 49(8):3239-3250.
   PubMed Web of Science ®Google Scholar
• APPELBAUM PC, JACOBS MR: Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. (2005) 8(5):510-517.
   PubMed Web of Science ®Google Scholar
• ANDES D, CRAIG WA: Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic–pharmacodynamic target. Antimicrob. Agents Chemother. (2006) 50(4):1376-1383.
   PubMed Web of Science ®Google Scholar
• GOLAN Y, McDERMOTT LA, JACOBUS NV et al.: Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. (2003) 52(2):208-213.
   PubMed Web of Science ®Google Scholar
• YU WL, JONES RN, HOLLIS RJ et al.: Molecular epidemiology of extended-spectrum β-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J. Clin. Microbiol. (2002) 40(12):4666-4669.
   PubMed Web of Science ®Google Scholar
• MILATOVIC D, SCHMITZ FJ, BRISSE S, VERHOEF J, FLUIT AC: In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob. Agents Chemother. (2000) 44(4):1102-1107.
   PubMed Web of Science ®Google Scholar
• SHETTY N, WILSON AP: Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (2000) 46(4):633-638.
   PubMed Web of Science ®Google Scholar
• DAWE RS, IBBOTSON SH, SANDERSON JB, THOMSON EM, FERGUSON J: A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br. J. Dermatol. (2003) 149(6):1232-1241.
   PubMed Web of Science ®Google Scholar
• Sitafloxacin: DU 6859, DU 6859A, Gracevit, sitafloxacin hydrate. Drugs R D (2003) 4(1):61-68.
   PubMedGoogle Scholar
• BHAGWAT SS, MUNDKUR LA, GUPTE SV, PATEL MV, KHORAKIWALA HF: The anti-methicillin-resistant Staphylococcus aureus quinolone WCK-771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob. Agents Chemother. (2006) 50(11):3568-3579.
   PubMed Web of Science ®Google Scholar
• JACOBS MR, BAJAKSOUZIAN S, WINDAU A et al.: In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob. Agents Chemother. (2004) 48(9):3338-3342.
   PubMed Web of Science ®Google Scholar
• PERIC M, JACOBS MR, APPELBAUM PC: Antianaerobic activity of a novel fluoroquinolone, WCK-771, compared to those of nine other agents. Antimicrob. Agents Chemother. (2004) 48(8):3188-3192.
   PubMed Web of Science ®Google Scholar
• PRATS G, ROSSI V, SALVATORI E, MIRELIS B: Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev. Anti Infect. Ther. (2006) 4(1):27-41.
   PubMedGoogle Scholar
• BARRETT JF: Oritavancin. Eli Lilly & Co. Curr. Opin. Investig. Drugs (2001) 2(8):1039-1044.
   PubMedGoogle Scholar
• BARRETT JF: Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs (2005) 6(8):781-790.
   PubMedGoogle Scholar
• SCHWALBE RS, McINTOSH AC, QAIYUMI S et al.: In vitro activity of LY-333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. (1996) 40(10):2416-2419.
   PubMed Web of Science ®Google Scholar
• BALTCH AL, SMITH RP, RITZ WJ, BOPP LH: Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY-333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. (1998) 42(10):2564-2568.
   PubMed Web of Science ®Google Scholar
• BOYLAN CJ, CAMPANALE K, IVERSEN PW et al.: Pharmacodynamics of oritavancin (LY-333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. (2003) 47(5):1700-1706.
   PubMed Web of Science ®Google Scholar
• MERCIER RC, HREBICKOVA L: Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti Infect. Ther. (2005) 3(3):325-332.
   PubMedGoogle Scholar
• SHAW JP, SEROOGY J, KANIGA K et al.: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(1):195-201.
   PubMed Web of Science ®Google Scholar
• GANDER S, KINNAIRD A, FINCH R: Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. (2005) 56(2):337-343.
   PubMed Web of Science ®Google Scholar
• STRYJEWSKI ME, O’RIORDAN WD, LAU WK et al.: Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. (2005) 40(11):1601-1607.
   PubMed Web of Science ®Google Scholar
• BARRIERE S, GENTER F, SPENCER E et al.: Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. (2004) 44(7):689-695.
   PubMed Web of Science ®Google Scholar
• EDNIE LM, RATTAN A, JACOBS MR, APPELBAUM PC: Antianaerobe activity of RBX-7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob. Agents Chemother. (2003) 47(3):1143-1147.
   PubMed Web of Science ®Google Scholar
• HUTCHINSON DK: Oxazolidinone antibacterial agents: a critical review. Curr. Top. Med. Chem. (2003) 3(9):1021-1042.
   PubMed Web of Science ®Google Scholar
• MATHUR T, BHATEJA P, PANDYA M, FATMA T, RATTAN A: In vitro activity of RBx-7644 (ranbezolid) on biofilm producing bacteria. Int. J. Antimicrob. Agents (2004) 24(4):369-373.
   PubMed Web of Science ®Google Scholar
• MATHUR T, SINGHAL S, KHAN S et al.: Adverse effect of staphylococci slime on in vitro activity of glycopeptides. Jpn J. Infect. Dis. (2005) 58(6):353-357.
   PubMed Web of Science ®Google Scholar
• WOOKEY A, TURNER PJ, GREENHALGH JM et al.: AZD-2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Clin. Microbiol. Infect. (2004) 10(3):247-254.
   PubMed Web of Science ®Google Scholar
• FLUIT AC, SCHMITZ FJ, VERHOEF J, MILATOVIC D: In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci. J. Antimicrob. Chemother. (2002) 50(2):271-276.
   PubMed Web of Science ®Google Scholar
• ANDEREGG TR, BIEDENBACH DJ, JONES RN: In vitro evaluation of AZD-2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob. Agents Chemother. (2002) 46(8):2662-2664.
   PubMed Web of Science ®Google Scholar
• YOON EJ, JO YW, CHOI SH et al.: In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic Gram-positive bacteria. Antimicrob. Agents Chemother. (2005) 49(6):2498-2500.
   PubMed Web of Science ®Google Scholar
• YONG D, YUM JH, LEE K et al.: In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. (2004) 48(1):352-357.
   PubMed Web of Science ®Google Scholar
• HAWSER S, LOCIURO S, ISLAM K: Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. (2006) 71(7):941-948.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER P, HAWSER S, ISLAM K: Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. (2003) 13(23):4217-4221.
   PubMed Web of Science ®Google Scholar
• KOHLHOFF SA, ROBLIN PM, REZNIK T et al.: In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob. Agents Chemother. (2004) 48(5):1885-1886.
   PubMed Web of Science ®Google Scholar
• YUAN Z, WHITE RJ: The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics. Biochem. Pharmacol. (2006) 71(7):1042-1047.
   PubMed Web of Science ®Google Scholar
• CHEN D, YUAN Z: Therapeutic potential of peptide deformylase inhibitors. Expert Opin. Investig. Drugs (2005) 14(9):1107-1116.
   PubMed Web of Science ®Google Scholar
• LOFLAND D, DIFUNTORUM S, WALLER A et al.: In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J. Antimicrob. Chemother. (2004) 53(4):664-668.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN-GIRISH S, McCOLM J, CLEMENTS JM et al.: Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2004) 48(12):4835-4842.
   PubMed Web of Science ®Google Scholar
• CREDITO K, LIN G, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of LBM-415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. (2004) 48(10):4033-4036.
   PubMed Web of Science ®Google Scholar
• WATTERS AA, JONES RN, LEEDS JA et al.: Antimicrobial activity of a novel peptide deformylase inhibitor, LBM-415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003 – 2004). J. Antimicrob. Chemother. (2006) 57(5):914-923.
   PubMed Web of Science ®Google Scholar
• MARGOLIS PS, HACKBARTH CJ, YOUNG DC et al.: Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. (2000) 44(7):1825-1831.
   PubMed Web of Science ®Google Scholar
• BOZDOGAN B, EDNIE L, CREDITO K, KOSOWSKA K, APPELBAUM PC: Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob. Agents Chemother. (2004) 48(12):4762-4765.
   PubMed Web of Science ®Google Scholar
• JONES RN, MOET GJ, SADER HS, FRITSCHE TR: Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J. Antimicrob. Chemother. (2004) 53(5):804-807.
   PubMed Web of Science ®Google Scholar
• ESCALADA MG, HARWOOD JL, MAILLARD JY, OCHS D: Triclosan inhibition of fatty acid synthesis and its effect on growth of Escherichia coli and Pseudomonas aeruginosa. J. Antimicrob. Chemother. (2005) 55(6):879-882.
   PubMed Web of Science ®Google Scholar
• ZHANG YM, LU YJ, ROCK CO: The reductase steps of the type II fatty acid synthase as antimicrobial targets. Lipids (2004) 39(11):1055-1060.
   PubMed Web of Science ®Google Scholar
• ONDEYKA JG, ZINK DL, YOUNG K et al.: Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy. J. Nat. Prod. (2006) 69(3):377-380.
   PubMed Web of Science ®Google Scholar
• YOUNG K, JAYASURIYA H, ONDEYKA JG et al.: Discovery of FabH/FabF inhibitors from natural products. Antimicrob. Agents Chemother. (2006) 50(2):519-526.
   PubMed Web of Science ®Google Scholar
• LIU W, HAN C, HU L et al.: Characterization and inhibitor discovery of one novel malonyl-CoA: acyl carrier protein transacylase (MCAT) from Helicobacter pylori. FEBS Lett. (2006) 580(2):697-702.
   PubMed Web of Science ®Google Scholar
• POHLMANN J, LAMPE T, SHIMADA M et al.: Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. Bioorg. Med. Chem. Lett. (2005) 15(4):1189-1192.
   PubMed Web of Science ®Google Scholar
• ZHENG CJ, YOO JS, LEE TG et al.: Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett. (2005) 579(23):5157-5162.
   PubMed Web of Science ®Google Scholar
• FATTOM A, FULLER S, PROPST M et al.: Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine (2004) 23(5):656-663.
   PubMed Web of Science ®Google Scholar
• VERNACHIO J, BAYER AS, LE T et al.: Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob. Agents Chemother. (2003) 47(11):3400-3406.
   PubMed Web of Science ®Google Scholar
• SHINEFIELD HR, BLACK S: Prospects for active and passive immunization against Staphylococcus aureus. Pediatr. Infect. Dis. J. (2006) 25(2):167-168.
   PubMed Web of Science ®Google Scholar
• SHINEFIELD H, BLACK S, FATTOM A et al.: Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. (2002) 346(7):491-496.
   PubMed Web of Science ®Google Scholar
• MALANGONI MA: Contributions to the management of intraabdominal infections. Am. J. Surg. (2005) 190(2):255-259.
   PubMed Web of Science ®Google Scholar
• JARVIS WR: Benchmarking for prevention: the Centers for Disease Control and Prevention’s National Nosocomial Infections Surveillance (NNIS) system experience. Infection (2003) 31(Suppl. 2):44-48.
   PubMed Web of Science ®Google Scholar
• FISHMAN N: Antimicrobial stewardship. Am. J. Med. (2006) 119(6 Suppl. 1):S53-S61 (Discussion S62-S70).
   PubMed Web of Science ®Google Scholar